Mitchell Davis

6.5k total citations · 2 hit papers
41 papers, 2.5k citations indexed

About

Mitchell Davis is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Mitchell Davis has authored 41 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hepatology, 20 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in Mitchell Davis's work include Hepatitis C virus research (25 papers), Hepatitis B Virus Studies (13 papers) and Liver Disease Diagnosis and Treatment (12 papers). Mitchell Davis is often cited by papers focused on Hepatitis C virus research (25 papers), Hepatitis B Virus Studies (13 papers) and Liver Disease Diagnosis and Treatment (12 papers). Mitchell Davis collaborates with scholars based in United States, Canada and Belgium. Mitchell Davis's co-authors include Eric Lawitz, Jonathan McCone, Joseph Galati, Eugene R. Schiff, Kenneth Koury, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison and Mark Sulkowski and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Mitchell Davis

38 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

2009 889 citations John G. McHutchison, Eric Lawitz et al. New England Journal of Medicine profile →
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

2010 515 citations Paul Y. Kwo, Eric Lawitz et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitchell Davis United States	17	2.2k	2.0k	422	239	186	41	2.5k
Bach‐Nga Pham France	16	394 0.2×	461 0.2×	104 0.2×	119 0.5×	7 0.0×	44	1.0k
Weibin Bao United States	14	454 0.2×	476 0.2×	86 0.2×	132 0.6×	6 0.0×	27	1.3k
Neena Sood India	18	201 0.1×	606 0.3×	122 0.3×	60 0.3×	21 0.1×	112	1.4k
Andrew Campbell United States	15	953 0.4×	967 0.5×	388 0.9×	170 0.7×		34	1.4k
G. S. A. McDonald Ireland	17	928 0.4×	881 0.5×	94 0.2×	158 0.7×	4 0.0×	50	1.7k
Greg Galler United States	9	1.2k 0.5×	1.7k 0.9×	210 0.5×	193 0.8×		13	2.4k
Wolf Peter Hofmann Germany	24	1.8k 0.8×	1.7k 0.9×	268 0.6×	107 0.4×	1 0.0×	72	2.3k
John Boitnott United States	15	1.2k 0.5×	1.1k 0.5×	173 0.4×	76 0.3×		20	1.7k
Jean‐Paul Viard France	20	76 0.0×	352 0.2×	654 1.5×	95 0.4×	34 0.2×	39	1.3k
Shahin Gharakhanian France	14	1.0k 0.5×	1.0k 0.5×	697 1.7×	121 0.5×		29	1.9k

Countries citing papers authored by Mitchell Davis

Since Specialization

Citations

This map shows the geographic impact of Mitchell Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Davis more than expected).

Fields of papers citing papers by Mitchell Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Davis. The network helps show where Mitchell Davis may publish in the future.

Co-authorship network of co-authors of Mitchell Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell Davis. A scholar is included among the top collaborators of Mitchell Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell Davis. Mitchell Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nabi, Rafiq, Vladimir N. Chouljenko, Farhana Musarrat, et al.. (2025). The Novel Oncolytic Herpes Simplex Virus Type‐1 (HSV‐1) Vaccine Strain VC2 Constitutively Expressing GM‐CSF Causes Increased Intratumoral T Cell Infiltration and Inhibition of Tumor Metastasis in the 4T1/Balb/c Mouse Model of Stage Four Breast Cancer. Journal of Medical Virology. 97(2). e70220–e70220. 1 indexed citations

Davis, Mitchell, et al.. (2024). The Pathophysiology, Diagnosis and Management of Chronic Inflammatory Skin Diseases. Discovery Medicine. 36(189). 1933–1933. 5 indexed citations

Davis, Mitchell, Mohammad Reza Movahed, Mehrtash Hashemzadeh, & Mehrnoosh Hashemzadeh. (2021). The presence of idiopathic thrombocytopenic purpura and incidence of acute non-ST elevation myocardial infarction. Annals of Hematology. 101(1). 21–26. 2 indexed citations

Davis, Mitchell, Mohammad Reza Movahed, Mehrtash Hashemzadeh, & Mehrnoosh Hashemzadeh. (2021). Evaluating association between idiopathic thrombocytopenic purpura and hypertension.. PubMed. 11(4). 405–409. 2 indexed citations

Aarsen, Kristine Van, et al.. (2019). P086: Awareness and barriers to access of a Ministry of Health mandated ‘Do Not Resuscitate’ confirmation form: An interim analysis. Canadian Journal of Emergency Medicine. 21(S1). S94–S95.

Gane, Edward, Mitchell L. Shiffman, K. Peter Etzkorn, et al.. (2017). Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen. Hepatology. 66(4). 1083–1089. 60 indexed citations

Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. PMC. 5 indexed citations

Gane, Edward, K. Peter Etzkorn, G. Morelli, et al.. (2016). Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study. Journal of Hepatology. 64(2). S147–S148. 23 indexed citations

Asselah, Tarik, Stephen Shafran, Sharon Bourgeois, et al.. (2016). Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in HCV Infected Patients Previously Treated with Placebo: Results of the Deferred Treatment Study (GS-US-342-1446 Study). Journal of Hepatology. 64(2). S827–S828. 1 indexed citations

10.

Everson, Gregory T., William Towner, Mitchell Davis, et al.. (2015). Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection. Annals of Internal Medicine. 4 indexed citations

11.

Gordon, Stuart C., Eric M. Yoshida, Eric Lawitz, et al.. (2013). Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Alimentary Pharmacology & Therapeutics. 38(1). 16–27. 17 indexed citations

12.

Kowdley, Kris V., Eric Lawitz, Tarek Hassanein, et al.. (2013). Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. The Lancet. 381(9883). 2100–2107. 227 indexed citations

13.

Läwitz, E., Mitchell Davis, M. Rodríguez‐Torres, et al.. (2013). 1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY. Journal of Hepatology. 58. S567–S567. 6 indexed citations

14.

Bronowicki, J.-P., Mitchell Davis, S. Flamm, et al.. (2012). 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS. Journal of Hepatology. 56. S6–S6. 31 indexed citations

15.

Gordon, Stuart C., Eric Lawitz, Bruce R. Bacon, et al.. (2011). Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaïVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin. Gastroenterology. 140(5). S–944. 2 indexed citations

16.

Gordon, Stuart C., E.J. Lawitz, Bruce R. Bacon, et al.. (2011). 428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S173–S174. 7 indexed citations

17.

Kwo, Paul Y., Eric Lawitz, Jonathan McCone, et al.. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. The Lancet. 376(9742). 705–716. 515 indexed citations breakdown →

18.

McHutchison, John G., Eric Lawitz, Mitchell L. Shiffman, et al.. (2009). Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. New England Journal of Medicine. 361(6). 580–593. 889 indexed citations breakdown →

19.

Kwo, Paul Y., E. Läwitz, Jonathan McCone, et al.. (2008). 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC. Journal of Hepatology. 48. S372–S372. 31 indexed citations

20.

Hammoud, Ghassan M., Kenneth J. Vega, Mark F. Sands, et al.. (2003). 347 Poor tolerability to high dose PEG interferon and ribavirin in HIV/HCV coinfected patients; initial results from a randomized multicenter trial. Hepatology. 38. 327–327. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact